Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 437087, 7 pages
http://dx.doi.org/10.1155/2014/437087
Clinical Study

Effects of Single Pill-Based Combination Therapy of Amlodipine and Atorvastatin on Within-Visit Blood Pressure Variability and Parameters of Renal and Vascular Function in Hypertensive Patients with Chronic Kidney Disease

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan

Received 21 February 2014; Revised 20 March 2014; Accepted 20 March 2014; Published 8 April 2014

Academic Editor: Pasquale Ditonno

Copyright © 2014 Kengo Azushima et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. P. Casas, W. Chua, S. Loukogeorgakis, P. Vallance, L. Smeeth, and A. D. Hingorani, “Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis,” The Lancet, vol. 366, no. 9502, pp. 2026–2033, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Ninomiya, V. Perkovic, F. Turnbull et al., “Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials,” British Medical Journal, vol. 347, article f5680, 2013. View at Publisher · View at Google Scholar
  3. T. Berl, L. G. Hunsicker, J. B. Lewis et al., “Cardiovascular outcomes in the irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy,” Annals of Internal Medicine, vol. 138, no. 7, pp. 542–I43, 2003. View at Google Scholar · View at Scopus
  4. S. Julius, S. E. Kjeldsen, M. Weber et al., “Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the value randomised trial,” The Lancet, vol. 363, no. 9426, pp. 2022–2031, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Dahlöf, P. S. Sever, N. R. Poulter et al., “Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial,” The Lancet, vol. 366, no. 9489, pp. 895–906, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Higashi, S. Sasaki, K. Nakagawa et al., “A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study,” Journal of the American College of Cardiology, vol. 35, no. 2, pp. 284–291, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Nazzaro, M. Manzari, M. Merlo et al., “Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects,” Hypertension, vol. 33, no. 2, pp. 719–725, 1999. View at Google Scholar · View at Scopus
  8. E. Leibovitz, M. Beniashvili, R. Zimlichman, A. Freiman, M. Shargorodsky, and D. Gavish, “Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients,” American Journal of Hypertension, vol. 16, no. 9, part 1, pp. 715–718, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. M. S. Zhou, R. Tian, E. A. Jaimes, and L. Raij, “Combination therapy of amlodipine and atorvastatin has more beneficial vascular effects than monotherapy in salt-sensitive hypertension,” American Journal of Hypertension, 2014. View at Publisher · View at Google Scholar
  10. T. Ogihara, K. Kikuchi, H. Matsuoka et al., “The Japanese society of hypertension guidelines for the management of hypertension (JSH 2009),” Hypertension Research, vol. 32, no. 1, pp. 3–107, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Matsuo, E. Imai, M. Horio et al., “Revised equations for estimated GFR from serum creatinine in Japan,” American Journal of Kidney Diseases, vol. 53, no. 6, pp. 982–992, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. T. G. Pickering, J. E. Hall, L. J. Appel et al., “Recommendations for blood pressure measurement in humans: an AHA scientific statement from the Council on High Blood Pressure Research Professional and Public Education Subcommittee,” Journal of Clinical Hypertension, vol. 7, no. 2, pp. 102–109, 2005. View at Google Scholar · View at Scopus
  13. P. M. Rothwell, S. C. Howard, E. Dolan et al., “Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke,” The Lancet Neurology, vol. 9, no. 5, pp. 469–480, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. J. H. Shin, J. Shin, B. K. Kim et al., “Within-visit blood pressure variability: relevant factors in the general population,” Journal of Human Hypertension, vol. 27, no. 5, pp. 328–334, 2013. View at Publisher · View at Google Scholar
  15. K. Takazawa, H. Kobayashi, N. Shindo, N. Tanaka, and A. Yamashina, “Relationship between radial and central aeterial pulse wave and evaluation of central aortic pressure using the radial arterial pulse wave,” Hypertension Research, vol. 30, no. 3, pp. 219–228, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. J. G. Kips, A. E. Schutte, S. J. Vermeersch et al., “Comparison of central pressure estimates obtained from SphygmoCor, Omron HEM-9000AI and carotid applanation tonometry,” Journal of Hypertension, vol. 29, no. 6, pp. 1115–1120, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. M.-R. Rezai, G. Goudot, C. Winters, J. D. Finn, F. C. Wu, and J. K. Cruickshank, “Calibration mode influences central blood pressure differences between SphygmoCor and two newer devices, the Arteriograph and Omron HEM-9000,” Hypertension Research, vol. 34, no. 9, pp. 1046–1051, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Tomiyama, M. Odaira, C. Matsumoto et al., “Effects of moderate-to-severe impairment of the estimated glomerular filtration rate and of proteinuria on the central hemodynamics and arterial stiffness in middle-aged healthy Japanese men,” International Journal of Nephrology, vol. 2011, Article ID 427471, 6 pages, 2011. View at Publisher · View at Google Scholar
  19. H. Mitsuhashi, K. Tamura, J. Yamauchi et al., “Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis,” Atherosclerosis, vol. 207, no. 1, pp. 186–190, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. S.-I. Masuda, K. Tamura, H. Wakui et al., “Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy,” Hypertension Research, vol. 32, no. 11, pp. 950–955, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Kanaoka, K. Tamura, M. Ohsawa et al., “Effects of aliskiren-based therapy on ambulatory blood pressure profile, central hemodynamics, and arterial stiffness in nondiabetic mild to moderate hypertensive patients,” Journal of Clinical Hypertension, vol. 14, no. 8, pp. 522–529, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Yamashina, H. Tomiyama, K. Takeda et al., “Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement,” Hypertension Research, vol. 25, no. 3, pp. 359–364, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Maeda, K. Tamura, T. Kanaoka et al., “Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY),” Clinical and Experimental Hypertension, vol. 34, no. 4, pp. 249–257, 2012. View at Google Scholar
  24. G. Viberti and N. M. Wheeldon, “Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect,” Circulation, vol. 106, no. 6, pp. 672–678, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Nitta, “Clinical assessment and management of dyslipidemia in patients with chronic kidney disease,” Clinical and Experimental Nephrology, vol. 16, no. 4, pp. 522–529, 2012. View at Google Scholar
  26. K. Douglas, P. G. O'Malley, and J. L. Jackson, “Meta-analysis: the effect of statins on albuminuria,” Annals of Internal Medicine, vol. 145, no. 2, pp. 117–124, 2006. View at Google Scholar · View at Scopus
  27. G. F. M. Strippoli, S. D. Navaneethan, D. W. Johnson et al., “Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials,” British Medical Journal, vol. 336, no. 7645, pp. 645–651, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Sandhu, N. Wiebe, L. F. Fried, and M. Tonelli, “Statins for improving renal outcomes: a meta-analysis,” Journal of the American Society of Nephrology, vol. 17, no. 7, pp. 2006–2016, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Kaneshiro, A. Ichihara, M. Sakoda, A. Kurauchi-Mito, K. Kinouchi, and H. Itoh, “Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan,” Kidney and Blood Pressure Research, vol. 32, no. 1, pp. 51–58, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. G. L. Bakris, P. A. Sarafidis, M. R. Weir et al., “Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial,” The Lancet, vol. 375, no. 9721, pp. 1173–1181, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Matsushita, M. van der Velde, B. C. Astor et al., “Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis,” The Lancet, vol. 375, no. 9731, pp. 2073–2081, 2010. View at Publisher · View at Google Scholar
  32. C. A. Herzog, R. W. Asinger, A. K. Berger et al., “Cardiovascular disease in chronic kidney disease. A clinical update from kidney disease improving global outcomes (KDIGO),” Kidney International, vol. 80, no. 6, pp. 572–586, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Ichihara, Y. Kaneshiro, M. Sakoda, T. Takemitsu, and H. Itoh, “Add-on amlodipine improves arterial function and structure in hypertensive patients treated with an angiotensin receptor blocker,” Journal of Cardiovascular Pharmacology, vol. 49, no. 3, pp. 161–166, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. J. N. Cohn, D. J. Wilson, J. Neutel et al., “Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia,” American Journal of Hypertension, vol. 22, no. 2, pp. 137–144, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Rikitake and J. K. Liao, “Rho GTPases, statins, and nitric oxide,” Circulation Research, vol. 97, no. 12, pp. 1232–1235, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Ito, O. Ito, N. Mori et al., “Atorvastatin upregulates nitric oxide synthases with Rho-kinase inhibition and Akt activation in the kidney of spontaneously hypertensive rats,” Journal of Hypertension, vol. 28, no. 11, pp. 2278–2288, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. P. M. Rothwell, S. C. Howard, E. Dolan et al., “Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension,” The Lancet, vol. 375, no. 9718, pp. 895–905, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Kawai, M. Ohishi, K. Kamide et al., “The impact of visit-to-visit variability in blood pressure on renal function,” Hypertension Research, vol. 35, no. 2, pp. 239–243, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Shimbo, J. D. Newman, A. K. Aragaki et al., “Association between annual visit-to-visit blood pressure variability and stroke in postmenopausal women: data from the women's health initiative,” Hypertension, vol. 60, no. 3, pp. 625–630, 2012. View at Publisher · View at Google Scholar
  40. C. J. McMullan, G. L. Bakris, R. A. Phillips, and J. P. Forman, “Association of BP variability with mortality among African Americans with CKD,” Clinical Journal of the American Society of Nephrology, vol. 8, no. 5, pp. 731–738, 2013. View at Publisher · View at Google Scholar
  41. K. Tamura, T. Kanaoka, M. Ohsawa et al., “Emerging concept of anti-hypertensive therapy based on ambulatory blood pressure profile in chronic kidney disease,” American Journal of Cardiovascular Disease, vol. 1, no. 3, pp. 236–243, 2011. View at Google Scholar
  42. G. Leoncini, F. Viazzi, G. Storace, G. Deferrari, and R. Pontremoli, “Blood pressure variability and multiple organ damage in primary hypertension,” Journal of Human Hypertension, vol. 27, no. 11, pp. 663–670, 2013. View at Google Scholar
  43. A. J. Webb, U. Fischer, Z. Mehta, and P. M. Rothwell, “Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis,” The Lancet, vol. 375, no. 9718, pp. 906–915, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Kawai, M. Ohishi, N. Ito et al., “Alteration of vascular function is an important factor in the correlation between visit-to-visit blood pressure variability and cardiovascular disease,” Journal of Hypertension, vol. 31, no. 7, pp. 1387–1395, 2013. View at Google Scholar
  45. C. B. Toal, P. A. Meredith, and H. L. Elliott, “Long-acting dihydropyridine calcium-channel blockers and sympathetic nervous system activity in hypertension: a literature review comparing amlodipine and nifedipine GITS,” Blood Press, vol. 21, supplement 1, pp. 3–10, 2012. View at Publisher · View at Google Scholar
  46. L. Siddiqi, J. A. Joles, P. L. Oey, and P. J. Blankestijn, “Atorvastatin reduces sympathetic activity in patients with chronic kidney disease,” Journal of Hypertension, vol. 29, no. 11, pp. 2176–2180, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Lewandowski, M. Siński, J. Bidiuk et al., “Simvastatin reduces sympathetic activity in men with hypertension and hypercholesterolemia,” Hypertension Research, vol. 33, no. 10, pp. 1038–1043, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. R. H. Chapman, J. Yeaw, and C. S. Roberts, “Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees,” BMC Cardiovascular Disorders, vol. 10, article 29, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. B. V. Patel, R. S. Leslie, P. Thiebaud et al., “Adherence with single-pill amlodipine/atorvastatin versus a two-pill regimen,” Vascular Health and Risk Management, vol. 4, no. 3, pp. 673–681, 2008. View at Google Scholar · View at Scopus